Case report: Transformative potential of trastuzumab deruxtecan in the first line treatment for advanced HER2-mutated lung adenocarcinoma: a case report and clinical insights

The treatment of non-small cell lung cancer (NSCLC), particularly lung adenocarcinoma (LUAD), represents a significant oncological challenge due to its aggressive behavior, high metastatic potential and poor prognosis. HER2 mutation is a rare but critical oncogenic driver associated with resistance...

Whakaahuatanga katoa

Ngā taipitopito rārangi puna kōrero

Ngā kaituhi matua:	Guanbin Huang, Tongtong Xia, Dongxiao Yang, Muwen Lin, Yiping Luo, Yuchan Li, Hualin Chen
Hōputu:	Artigo
Reo:	Inglês
I whakaputaina:	Frontiers Media S.A. 2025-04-01
Rangatū:	Frontiers in Pharmacology
Ngā marau:	HER2-mutant NSCLC trastuzumab deruxtecan antibody-drug conjugate first line treatment central nervous system metastases
Urunga tuihono:	https://www.frontiersin.org/articles/10.3389/fphar.2025.1564834/full
Ngā Tūtohu:	Tāpirihia he Tūtohu Kāore He Tūtohu, Me noho koe te mea tuatahi ki te tūtohu i tēnei pūkete!